SBIR/STTR Research Award
CHARACTERIZATION OF A POTENTIAL NEW ANTIMICROBIAL AGENT
Award amount
$50,000Program and phase
SBIR · Phase IAward year
1990Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Epicentre Technologies Corporation
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
RECENTLY, RESEARCHERS FOUND THAT THE BACTERIAL PHYTOTOXIN TAGETITOXIN IS A POTENT INHIBITOR OF ESCHERICHIA COLI RNA POLYMERASE IN VITRO. THIS COMMON MECHANISM OF ACTION WITH KNOWN ANTIBIOTICS SUCH AS RIFAMPICIN AND STREPTOLYDIGINSUGGESTS THAT TAGETITOXIN OR ITS DERIVATIVES HAVE POTENTIAL AS NEW ANTIMICROBIALS. STRUCTURAL INFORMATION OBTAINED TO DATE INDICATES THAT TAGETITOXIN IS MUCH DIFFERENT THAN THE KNOWN ANTIBIOTICS THAT ARE RNA POLYMERASE INHIBITORS. THE GOALS OF PHASE I RESEARCH ARE: (1) TO INVESTIGATE MEDIA AND FERMENTATION PARAMETERS THAT WILL ALLOW EFFICIENT AND CONSISTENT GROWTH OF THE TOXIN-PRODUCING BACTERIUM, ALONG WITH PRODUCTION OF REPRODUCIBLY HIGH LEVELS OF TAGETITOXIN; (2) TO SCALE UP AND IMPROVE PURIFICATION METHODS; AND (3) TO DETERMINE THE EXACT STRUCTURE OF TAGETITOXIN BY USING INSTRUMENTAL, CHEMICAL, AND ENZYMATIC METHODS. THE STRUCTURAL KNOWLEDGE OBTAINED IN PHASE I WILL BE USED IN PHASE II TO SYNTHESIZE AND EVALUATE NEW TAGETITOXIN ANALOGS FOR BACTERIAL PERMEABILITY, RNA POLYMERASE INHIBITORY ACTIVITY, ANTIMICROBIAL ACTIVITY, AND STRUCTURE/ACTIVITY RELATIONSHIPS, WITH THE ULTIMATE AIM OF DEVELOPING TAGETITOXIN OR ITS DERIVATIVES INTO A NEW FAMILY OF ANTIMICROBIAL PRODUCTS FOR HUMAN AND/OR VETERINARY MEDICINE.
Technology keywords
Not reported